Comprehensive Genomic Profiling of Neuroendocrine Carcinomas of the Gastrointestinal System

DSpace/Manakin Repository

Comprehensive Genomic Profiling of Neuroendocrine Carcinomas of the Gastrointestinal System
 
Yachida, Shinichi; Totoki, Yasushi; Noe, Michael; Nakatani, Yoichiro; Horie, Masafumi; Kawasaki, Kenta; Nakamura, Hiromi; Saito-Adachi, Mihoko; Suzuki, Masami; Takai, Erina; Hama, Natsuko; Higuchi, Ryota; Hirono, Seiko; Shiba, Satoshi; Kato, Mamoru; Furukawa, Eisaku; Arai, Yasuhito; Rokutan, Hirofumi; Hashimoto, Taiki; Mitsunaga, Shuichi; Kanda, Mitsuro; Tanaka, Hidenori; Takata, So; Shimomura, Ayaka; Oshima, Minoru; Hackeng, Wenzel M; Okumura, Tomoyuki; Okano, Keiichi; Yamamoto, Masakazu; Yamaue, Hiroki; Morizane, Chigusa; Arihiro, Koji; Furukawa, Toru; Sato, Toshiro; Kiyono, Tohru; Brosens, Lodewijk A A; Wood, Laura D; Hruban, Ralph H; Shibata, Tatsuhiro
(2022) Cancer Discovery, volume 12, issue 3, pp. 692 - 711
(Article)
Abstract
The neuroendocrine carcinoma of the gastrointestinal system (GIS-NEC) is a rare but highly malignant neoplasm. We analyzed 115 cases using whole-genome/exome sequencing, transcriptome sequencing, DNA methylation assays, and/or ATAC-seq and found GIS-NECs to be genetically distinct from neuroendocrine tumors (GIS-NET) in the same location. Clear genomic differences were also evident ... read more
Download/Full Text
Open Access version via Utrecht University Repository Publisher version
Version on publisher website for UU-students and staff
Version on publisher website
 
Keywords: Oncology, Journal Article
DOI: https://doi.org/10.1158/2159-8290.CD-21-0669
ISSN: 2159-8274
Publisher: American Association for Cancer Research Inc.
Note: Funding Information: We thank all patients and their families who participated in this study, Y. Kawahara (Osaka University, Osaka, Japan), Y. Shimada (Kyoto University, Kyoto, Japan), J. Shibahara (Kyorin University, Tokyo, Japan), T. Sakatani (Nippon Medical School Hospital, Tokyo, Japan), T. Ushiku (The University of Tokyo, Tokyo, Japan), A. Fukagawa (National Cancer Center Research Institute, Tokyo, Japan) for expert advice, and E. Arakawa, K. Igarashi (National Cancer Center Research Institute, Tokyo, Japan), and M. Oda (Hiroshima University Hospital, Hiroshima, Japan) for expert technical assistance. This work was supported by grants from the National Cancer Center Research and Development Fund (29-A-6 to T. Shibata); Practical Research for Innovative Cancer Control from the Japan Agency for Medical Research and Development (AMED; JP21ck0106558 to S. Yachida; JP21ck0106693 to S. Yachida; JP21ck0106690 to S. Yachida, Y. Totoki, and T. Shibata; JP21ck0106547 to S. Yachida and T. Shibata; JP15ck0106138 and JP16ck0106138 to C. Morizane); Project for Cancer Research and Therapeutic Evolution (P-CREATE) from AMED (JP17cm0106612 to S. Yachida, Y. Totoki, and E. Takai); United States–Japan Cooperative Medical Science Program from AMED (JP20jk0210009 to S. Yachida, T. Kiyono, and T. Shibata); Integrated Frontier Research for Medical Science Division, Institute for Open and Transdisciplinary Research Initiatives, Osaka University (to S. Yachida); Joint Research Project of the Institute Medical Science, The University of Tokyo (to S. Yachida and T. Shibata); the Takeda Science Foundation (to S. Yachida); the Yasuda Medical Foundation (to S. Yachida); the Mitsubishi Foundation (to S. Yachida); and the Princess Takamatsu Cancer Research Fund (to S. Yachida). The National Cancer Center Research Biobank is supported by the National Cancer Center Research and Development Fund, Japan. Publisher Copyright: © 2021 The Authors.
(Peer reviewed)